Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma

Gut and Liver

Volumn 8, Issue 2, 2014, Pages 177-185

  Lee, Hyun Jung ^a   Yeon, Jong Eun ^a   Suh, Sang Jun ^a   Lee, Sun Jae ^a   Yoon, Eileen L ^a   Kang, Keunhee ^a   Yoo, Yang Jae ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yim, Hyung Joon ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Glypican 3; Hepatocellular carcinoma; Osteopontin

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; GLYPICAN 3; OSTEOPONTIN; TUMOR MARKER; GLYPICAN; GPC3 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER ELISA KIT; CANCER PATIENT; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CARCINOMA, HEPATOCELLULAR; EVALUATION STUDY; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897004411     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2014.8.2.177     Document Type: Article

References (36)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15 Suppl 4:5-13.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
3. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119-126. (Pubitemid 351199465)
4. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
5. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32(4 Pt 1):842-846.
6. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-438.
7. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-2176. (Pubitemid 24035747)
8. Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002;49:235-238. (Pubitemid 34289526)
9. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502.
10. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
11. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, over-expressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25. (Pubitemid 36629398)
12. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 2010;14:2037-2044.
13. El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 2008;13:4276-4284. (Pubitemid 351599683)
14. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK. Osteopontin as a target for cancer therapy. Front Biosci 2008;13:4361-4372. (Pubitemid 351599688)
15. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003;98:119-127.
16. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19-24. (Pubitemid 34299209)
17. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
18. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536. (Pubitemid 34260532)
19. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
20. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501. (Pubitemid 32777726)
21. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-810. (Pubitemid 29086731)
22. Murthy SS, Shen T, De Rienzo A, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000;19:410-416. (Pubitemid 30077342)
23. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179-5184. (Pubitemid 27498138)
24. Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010;16:4410-4415.
25. Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010;25:129-137.
26. Qiao SS, Cui ZQ, Gong L, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2011;58:1718-1724.
27. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
28. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-575. (Pubitemid 32328514)
29. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004;121:228-241. (Pubitemid 39387464)
30. Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-2692.
31. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006;101:2051-2059. (Pubitemid 44337631)
32. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:709-717. (Pubitemid 44337931)
33. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-490.
34. Lorena D, Darby IA, Gadeau AP, et al. Osteopontin expression in normal and fibrotic liver altered liver healing in osteopontin-deficient mice. J Hepatol 2006;44:383-390. (Pubitemid 43069221)
35. Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
36. Urtasun R, Lopategi A, George J, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V) β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012;55:594-608.